A new report from Deloitte highlights that surging demand for weight loss and diabetes drugs, such as Wegovy and Zepbound, is fueling a 'bubble effect' in the pharmaceutical sector, significantly boosting profitability but also increasing risk concentration within the industry [1]. Pharmaceutical R&D returns for the world's top 20 pharma companies have improved for a third consecutive year, reaching 7%, a rise attributed almost entirely to high-forecast assets like glucagon-like peptide receptor agonists (GLP-1s) [1].
For the first time in 16 years, obesity treatments have overtaken oncology as the largest contributor to late-stage pipeline value, with obesity drugs now accounting for an estimated 38% of all projected commercial inflows from the 2025 late-stage pipeline, compared to just 1% in 2022 [1]. If GLP-1/GIP assets are excluded, the industry's rate of return drops sharply to 2.9%, down from 3.8% in 2024, revealing underlying weakness in the broader sector [1]. Obesity assets now represent about 25% of total forecast sales in the late-stage pipeline, while oncology's share has slipped to 20% [1].
Deloitte's analysis warns that this boom has led to a significant concentration of risk, with just 54 mega-blockbuster indications—representing only 9% of the late-stage cohort—projected to generate roughly 70% of total risk-adjusted peak sales [1]. The report notes that while overreliance on blockbuster drugs is not new, the current degree of concentration is unprecedented, creating a high-stakes environment where a small number of assets can disproportionately impact overall returns [1].
Hanno Ronte, Life Sciences and Healthcare Partner at Deloitte, stated that the market for GLP-1s has become truly transformative for patients and health systems, but the sector is now highly sensitive to shocks in these specific therapeutic areas [1]. Scientists are still investigating the full benefits of GLP-1s, with some already approved for reducing cardiovascular risks and treating liver and kidney disease [1].
CONCLUSION
Deloitte's report underscores that while weight loss and diabetes drugs are driving unprecedented growth in the pharmaceutical sector, this is creating a risky 'bubble effect' due to heavy reliance on a small number of blockbuster assets. The market is experiencing both transformative benefits and heightened vulnerability, with future sector performance closely tied to the continued success of these drugs.